Optimizing the benefits of bisphosphonates in osteoporosis: The importance of appropriate calcium intake

Treatments in Endocrinology

Volumn 5, Issue 6, 2006, Pages 375-383

  Boonen, Steven ^a,b   Bouillon, Roger ^a,b   Haentjens, Patrick ^c   Vanderschueren, Dirk ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM CARBONATE; ESTROGEN; PLACEBO; RISEDRONIC ACID; VITAMIN D; CALCIUM INTAKE;

ABDOMINAL PAIN; CALCIUM INTAKE; CLINICAL TRIAL; CONFUSION; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG EFFECT; FRACTURE; HUMAN; HYPERCALCEMIA; META ANALYSIS; MUSCLE WEAKNESS; NAUSEA; NEPHROLITHIASIS; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOCIOECONOMICS; SYSTEMATIC REVIEW; VOMITING; DRUG PACKAGING; OSTEOPOROSIS, POSTMENOPAUSAL;

CALCIUM, DIETARY; DIPHOSPHONATES; DRUG PACKAGING; HUMANS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 33751219845     PISSN: 11756349     EISSN: 11756349     Source Type: Journal    
DOI: 10.2165/00024677-200605060-00006     Document Type: Review

References (62)

1. Consensus Development Conference: prophylaxis and treatment of osteoporosis. Am J Med 1991 Jan; 90: 107-10
2. Kannus P, Niemi S, Parkkari J, et al. Hip fractures in Finland between 1970 and 1997 and predictions for the future. Lancet 1999 Mar; 353: 802-5
3. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005 Mar; 16 Suppl. 2: S3-7
4. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000; 11: 669-74
5. Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporos Int 2000; 11: 556-61
6. Browner WS, Pressman AR, Nevitt MC, et al. Mortality following fractures in older women: the Study of Osteoporotic Fractures. Arch Intern Med 1996 Jul; 156: 1521-5
7. Keene GS, Parker MJ, Pryor GA. Mortality and morbidity after hip fractures. BMJ 1993 Nov; 307: 1248-50
8. Johnell O, Gullberg B, Allander E, et al. The apparent incidence of hip fracture in Europe: a study of national register sources. MEDOS Study Group. Osteoporos Int 1992 Nov; 2: 298-302
9. Johnell O, Gullberg B, Kanis J, et al. The hospital burden of vertebral fracture in Europe: a study of national register sources. Osteoporos Int 1997; 7: 138-44
10. Chapurlat RD, Bauer DC, Nevitt M, et al. Incidence and risk factors of a second hip fracture in elderly women: the Study of Osteoporotic Fractures. Osteoporos Int 2003 Apr; 14: 130-6
11. Colon-Emeric C, Kuchibhatla M, Pieper C, et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int 2003 Nov; 14: 879-83
12. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001 Jan; 285: 320-3
13. Haentjens P, Autier P, Barette M, et al. The economic cost of hip fractures among elderly women: a one-year, prospective, observational cohort study with matched-pair analysis. Belgian Hip Fracture Study Group. J Bone Joint Surg Am 2001 Apr; 83-A: 493-500
14. European Commission. Report on osteoporosis in the European Community: action for prevention, 1998 [online]. Available from URL: http://www.osteofound. org/publications/pdf/eu_report_98.pdf/ [Accessed 2005 Dec 23]
15. Nieves JW, Komar L, Cosman F, et al. Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr 1998 Jan; 67: 18-24
16. Boonen S, Laan RF, Barton IP, et al. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005 Oct; 16: 1291-8
17. Hauselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 2003 Jan; 14: 2-12
18. Reginster J, Minne HW, Sorenson OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis: Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83-91
19. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000 Nov; 85: 4118-24
20. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997 Sep; 337: 670-6
21. Chapuy MC, Chapuy P, Meunier PJ. Calcium and vitamin D supplements: effects on calcium metabolism in elderly people. Am J Clin Nutr 1987 Aug; 46: 324-8
22. Yates AA, Schlicker SA, Suitor CW. Dietary reference intakes: the new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J Am Diet Assoc 1998 Jun; 98: 699-706
23. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997; 7: 439-43
24. 3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk. The Decalyos II Study. Osteoporos Int 2002 Mar; 13: 257-64
25. Institute of Medicine. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press, 1997
26. Ervin RB, Wang C-Y, Wright JD, et al. Dietary intake of selected minerals for the United States population: 1999-2000. Advance data from vital and health statistics, 27 April 2004; no. 341 [online]. Available from URL: http://www.cdc.gov/nchs/data/ad/ad341.pdf/ [Accessed 2005 Dec 20]
27. Heaney R, Magowan S, Zhou X, et al. Prevalence of low calcium intake in postmenopausal osteoporotic women: the need for supplementation. ASBMR 27th annual meeting; 2005 Sep 23-27; Nashville (TN): M276
28. RECORD Trial Group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005 May; 365: 1621-8
29. Grant A. Prevention of low-trauma fractures in older people: author's reply. Lancet 2005 Aug; 366: 543-4
30. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006 Feb; 354: 669-83
31. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women: Study of Osteoporotic Fractures Research Group. N Engl J Med 1995 Mar; 332: 767-73
32. Stafford RS, Drieling RL, Hersh AL. National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Med 2004 Jul; 164: 1525-30
33. Dawson-Hughes B, Bradshaw MP. Bisphosphonate users do not purchase enough calcium to ensure sufficient supplementation. ASBMR 27th Annual Meeting; 2005 Sep 23-27; Nashville (TN): SU422
34. Bischoff HA, Stähelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003 Feb; 18: 343-51
35. Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000 Jun; 15: 1113-8
36. Bischoff-Ferrari HA, Orav J, Dawson-Hughes B. Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Arch Intern Med 2006 Feb; 166: 424-30
37. Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic factures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res 2004; 19: 370-8
38. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992 Dec; 327: 1637-42
39. Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994 Apr; 308: 1081-2
40. Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005 Apr; 330: 1003-6
41. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005 May; 293: 2257-64
42. Shea BJ, Wells, G, Cranney A, et al. Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev 2004; (1): CD004526.pub2
43. 3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab 2000; 85: 3011-9
44. Xu L, McElduff P, D'Este C, et al. Does dietary calcium have a protective effect on bone fractures in women? A meta-analysis of observational studies. Br J Nutr 2004 Apr; 91: 625-34
45. Boonen S, Rizzoli R, Meunier PJ, et al. The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report. Osteoporos Int 2004 Jul; 15: 511-9
46. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis: IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002 Aug; 23: 570-8
47. Sunyecz JA, Weisman SM. The role of calcium in osteoporosis drug therapy. J Womens Health (Larchmt) 2005; 14: 180-92
48. Whitson HE, Lobaugh B, Lyles KW. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone. Bone 2006; 39 (4): 954-8
49. Parfitt AM. Skeletal and mineral homeostasis. In: Deluca HF, Frost HM, Jee WSS, et al., editors. Osteoporosis: recent advances in pathogenesis and treatment. Baltimore (MD): University Park Press, 1981
50. Mishra A, Wong L, Jonklaas J. Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. Endocrine 2001 Mar; 14: 159-64
51. Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphosphonate ther-apy in occult vitamin D deficiency. N Engl J Med 2003 Apr; 348: 1503-4
52. Stuckey BG, Lim EM, Kent GN, et al. Bisphosphonate therapy for Paget's disease in a patients with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission. J Bone Miner Res 2001 Sep; 16: 1719-23
53. Gutteridge DH, Retallack RW, Ward LC, et al. Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study. Bone 1996 Oct; 19: 387-94
54. Sirola J, Kroger H, Sandini L, et al. Interaction of nutritional calcium and HRT in prevention of postmenopausal bone loss: a prospective study. Calcif Tissue Int 2003 Jun; 72: 659-65
55. Ravn P, Clemmesen B, Riis BJ, et al. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996 Nov; 19: 527-33
56. Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women: Alendronate Osteoporosis Prevention Study Group. Bone 1999 Mar; 24: 237-44
57. Tankó LB, Mouritzen U, Lehmann HJ, et al. Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. Bone 2003 Jun; 32: 687-93
58. Rackoff PJ, Sebba A. Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis. Treat Endocrinol 2005; 4: 245-51
59. Dawson-Hughes B, Bradshaw MP. Bisphosphonate users do not purchase enough calcium to ensure sufficient supplementation [abstract]. J Bone Miner Res 2005; 20: S287
60. Ringe JD, van der Geest SAP, Möller G. Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: innovative approach to improve correct intake and drug adherence. Drugs Aging 2006; 23: 569-78
61. Michaëlsson K, Melhus H, Bellocco R, et al. Dietary calcium and vitamin D intake in relation to osteoporotic fracture risk. Bone 2003 Jun; 32: 694-703
62. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. Am J Clin Nutr 2000 Sep; 72: 745-50